Although low-density lipoprotein cholesterol (LDL-C) can now be effectively reduced, substantial residual risk of acute ischemic cardiovascular events persists. Lipoprotein(a) [Lp(a)] is an established causal risk factor for atherosclerotic cardiovascular disease (ASCVD), yet its mechanistic links to plaque vulnerabili...
Quan-Hao Sun, Ya-Jie Wang, Xiao-Ya Li et al.· Biomedicines· 0 citations
Dose-response analysis showed that ecnoglutide exhibited a clear dose-dependent relationship for HbA1c, FPG, and body weight at doses ranging from 0.4 to 1.2 mg, while PPG was less affected by dose.
Yi-Xuan Feng, Chang-Xin Sun, Xiao-Ya Li et al.· Frontiers in Endocrinology· 0 citations
Apolipoprotein B (ApoB) serves as the structural backbone of triglyceride (TG)-rich lipoproteins and low-density lipoprotein (LDL) particles and plays a key role in lipid transport. A growing body of evidence indicates that circulating ApoB levels are closely associated with the development of cardiovascular diseases s...
Ling-Ling Li, Yi-Xuan Feng, Xiao-Ya Li et al.· Frontiers in Cardiovascular...· 0 citations
Background: Polydatin has shown anti-inflammatory, antioxidant, and cytoprotective effects in preclinical studies. Its development is limited by low oral bioavailability, extensive metabolism, and poorly defined tissue exposure. Objectives: This review summarizes the pharmacology and delivery systems of polydatin, dist...
PH exerts a protective effect on HUVECs and prevents AS by regulating the YTHDF2/DRP1 axis to restore mitochondrial homeostasis, thereby providing a novel therapeutic approach for AS.
Yu-Juan Li, Xiao-Nan Zhang, Sheng-Jie Yang et al.· Journal of Advanced Research· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.